The video interview discusses John Tomtishen’s career, changes across the cell therapy field, and his perspectives on product characterization, CMC, scalability, and bringing future cell therapies to more patients.
Approach:
Interview: The video was produced in partnership with IBTV and features Tomtishen, Global Head of Cell Therapy Field Application Scientists and Strategic Alliances at Catalent.
Topics: The discussion covers early product characterization and CMC, technologies and manufacturing strategies for scalability, and steps the industry could take to bring future cell therapies to more patients.
Key Findings:
Tomtishen explains why developers should prioritize product characterization and CMC early in development.
The interview explores technologies and manufacturing strategies that could improve scalability.
Tomtishen shares his perspective on what the industry must do to bring the next generation of transformative cell therapies to more patients.
Interpretation:
The interview presents Tomtishen’s perspective on development and manufacturing considerations in the cell therapy field.
Limitations:
The provided context does not include the full interview or further details about the technologies and strategies discussed.
Adults assigned to nonnutritive sweetened beverages or water maintained weight reductions through 104 weeks, with no statistically significant difference between groups.
